Median Technologies Completes Capital Increase to €50M
Median Technologies announced on Wednesday the successful completion of its capital increase without preferential subscription rights, raised to €50M from the initially planned €40M. The global public offering was oversubscribed, allowing the full implementation of the offer reserved for three guaranteeing investors, thus diversifying the company's shareholder base.
Fundraising Increased to €50M Due to Oversubscription
Median Technologies, the developer of the Eyonis software for early cancer diagnosis using artificial intelligence, announced on Wednesday the success of its capital increase. The global offering, launched on May 27 and initially set at €40M, was oversubscribed multiple times by European, American, and British institutional investors, as well as French individual investors. Due to this level of demand, the share reserve benefiting three guaranteeing investors (Katarina Martinson AB, Venture S.a.r.l, and Nordica Life (Bermuda) Ltd) was fully deployed for an additional €10M. The transaction thus totals €50M gross, including the issuance premium, with 10 million new shares issued at a price of €5 per share.
Use of Funds and Extended Financial Autonomy
Median Technologies will allocate the net proceeds from the increase to accelerate the commercialization of Eyonis LCS in the United States and its launch in targeted European countries following the expected CE marking in the coming weeks, as well as to the development of Eyonis for additional oncological indications and the general needs of the company. This fundraising extends the cash visibility until the first half of 2028. Fredrik Brag, CEO and founder, notes that the full exercise of the 12 million subscription warrants issued in July 2025 and still outstanding could extend this autonomy until mid-2029.
Strengthening the Round Table and Strategic Reaction
The reserved offer was fully subscribed by the three guarantors. In total (Global Offering and reserved offer combined), Katarina Martinson AB subscribed for 2,666,667 new shares in the Global Offering and 1,333,333 in the reserved offer; Venture S.a.r.l subscribed for 933,333 and 466,667 respectively, and Nordica Life (Bermuda) Ltd 400,000 and 200,000. Following the operation, their shareholdings are established at 4,320,000 shares for Katarina Martinson AB, 1,512,000 for Venture S.a.r.l, and 648,000 for Nordica Life (Bermuda) Ltd. The company also welcomes the active participation of Lion Point Capital, which entered the capital in 2025. The settlement-delivery and admission to trading on Euronext Growth Paris are scheduled for June 5, 2026 under the same ISIN code (FR0011049824).
